​​Emerging ADCs and Their Role in Advanced Lung Cancer Treatment​

Emerging ADCs and Their Role in Advanced Lung Cancer Treatment.jpg

Antibody drug conjugates are novel agents developed for the treatment of a variety of cancers, including lung cancer. This webinar will describe the mechanism of action of these agents and will inform the audience of the current use and areas of development. Since these agents are very novel, it is important to discuss the unique side effects associated with treatment and the management of these unique toxicities.

Learning Objectives: 
At the end of the webinar, learners will be able to: 

  1. Describe and understand the mechanism of action of ADC. 
  2. Identify drugs in development and indications. 
  3. Differentiate drug-related adverse events and management of side effects. 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

The International Association for the Study of Lung Cancer designates the live format for this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Aug 22, 2023 -
Aug 22, 2023

August 22, 2023

CME Accredited



Antoinette Wozniak


Professor of Medicine and Interim Chief of the Division of Hematology / Oncology
University of Pittsburgh
Bennjamin Levy
Benjamin Levy


Johns Hopkins University School of Medicine
Daniel Tan
Daniel Tan
Committee Member
National Cancer Centre Singapore
Alona Zer
Alona Zer


Head of the Department of Medical Oncology
Rambam Health Care Campus, Haifa, Israel